Search Results - "Etienne Chatelut"

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies by Widmer, Nicolas, Bardin, Christophe, Chatelut, Etienne, Paci, Angelo, Beijnen, Jos, Levêque, Dominique, Veal, Gareth, Astier, Alain

“…Abstract Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration generates a complex step in the pharmacokinetics (PK) of…”
Get full text

Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics by Paci, Angelo, Veal, Gareth, Bardin, Christophe, Levêque, Dominique, Widmer, Nicolas, Beijnen, Jos, Astier, Alain, Chatelut, Etienne

“…Abstract Most anticancer drugs are characterised by a steep dose–response relationship and narrow therapeutic window. Inter-individual pharmacokinetic (PK)…”
Get full text

Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib by Puszkiel, Alicja, Noé, Gaëlle, Bellesoeur, Audrey, Kramkimel, Nora, Paludetto, Marie-Noëlle, Thomas-Schoemann, Audrey, Vidal, Michel, Goldwasser, François, Chatelut, Etienne, Blanchet, Benoit

“…Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activated…”
Get full text

Therapeutic drug monitoring in cancer – Are we missing a trick? by Bardin, Christophe, Veal, Gareth, Paci, Angelo, Chatelut, Etienne, Astier, Alain, Levêque, Dominique, Widmer, Nicolas, Beijnen, Jos

“…Abstract Therapeutic drug monitoring (TDM) can be defined as the measurement of drug in biological samples to individualise treatment by adapting drug dose to…”
Get full text

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy by Clarke, William A., Chatelut, Etienne, Fotoohi, Alan K., Larson, Richard A., Martin, Jennifer H., Mathijssen, Ron H.J., Salamone, Salvatore J.

“…Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology,…”
Get full text

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective by Le Louedec, Félicien, Leenhardt, Fanny, Marin, Clémence, Chatelut, Étienne, Evrard, Alexandre, Ciccolini, Joseph

“…Immune check-point inhibitors are drugs that are markedly different from other anticancer drugs because of their indirect mechanisms of antitumoral action and…”
Get full text

Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr by Le Louedec, Félicien, Puisset, Florent, Thomas, Fabienne, Chatelut, Étienne, White‐Koning, Mélanie

“…Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model‐informed precision dosing (MIPD) approach. The mapbayr package was…”
Get full text

Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients by Gallais, Fanny, Oberic, Lucie, Faguer, Stanislas, Tavitian, Suzanne, Lafont, Thierry, Marsili, Sabrina, Brice, Aurélie, Chatelut, Etienne, Puisset, Florent

“…High-dose methotrexate is used for treating several types of cancer. However, it is associated with a high risk of acute kidney injury (AKI), especially in…”
Get full text

Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance by White-Koning, Melanie, Paludetto, Marie Noëlle, Le Louedec, Félicien, Gladieff, Laurence, Chevreau, Christine, Chatelut, Etienne, Puisset, Florent

“…Purpose While doses of carboplatin are mostly individualized according to the Calvert equation based on estimated Glomerular Filtration Rate (eGFR), there is…”
Get full text

Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day by Ranchon, Florence, Chatelut, Étienne, Lambert, Juliette, Sesques, Pierre, Thibault, Constance, Madelaine, Isabelle, Rioufol, Catherine, Diéras, Véronique, Cazin, Jean-Louis

“…Antibody Drug Conjugates (ADC) and bispecific antibodies are booming and were the subject of the scientific event proposed by the French Society of Oncological…”
Get more information

Correction to: Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance by White-Koning, Melanie, Paludetto, Marie Noëlle, Le Louedec, Félicien, Gladieff, Laurence, Chevreau, Christine, Chatelut, Etienne, Puisset, Florent

“…A correction to this paper has been published: https://doi.org/10.1007/s00280-021-04268-4…”
Get full text

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data by Le Louedec, Félicien, Gallais, Fanny, Thomas, Fabienne, White-Koning, Mélanie, Allal, Ben, Protin, Caroline, Ysebaert, Loïc, Chatelut, Étienne, Puisset, Florent

“…Therapeutic drug monitoring of ibrutinib is based on the area under the curve of concentration vs. time (AUC ) instead of trough concentration (C ) because of…”
Get full text

Human renal function maturation: a quantitative description using weight and postmenstrual age by Rhodin, Malin M., Anderson, Brian J., Peters, A. Michael, Coulthard, Malcolm G., Wilkins, Barry, Cole, Michael, Chatelut, Etienne, Grubb, Anders, Veal, Gareth J., Keir, Michael J., Holford, Nick H. G.

“…This study pools published data to describe the increase in glomerular filtration rate (GFR) from very premature neonates to young adults. The data comprises…”
Get full text

Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach by Metsu, David, Lanot, Thomas, Fraissinet, François, Concordet, Didier, Gayrard, Véronique, Averseng, Manon, Ressault, Alice, Martin-Blondel, Guillaume, Levade, Thierry, Février, Frédéric, Chatelut, Etienne, Delobel, Pierre, Gandia, Peggy

“…Dolutegravir therapeutic drug monitoring (TDM) could be improved by measuring the unbound dolutegravir plasma concentration (Cu), particularly in patients…”
Get full text

International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients—An Analysis of the Medical Literature by Lichtman, Stuart M, Wildiers, Hans, Chatelut, Etienne, Steer, Christopher, Budman, Daniel, Morrison, Vicki A, Tranchand, Brigitte, Shapira, Iuliana, Aapro, Matti

“…The elderly comprise the majority of patients with cancer and are the recipients of the greatest amount of chemotherapy. Unfortunately, there is a lack of data…”
Get full text

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients by Le Louedec, Félicien, Alix‐Panabières, Catherine, Lafont, Thierry, Allal, Ben C., Garrel, Renaud, Digue, Laurence, Guigay, Joël, Cupissol, Didier, Delord, Jean‐Pierre, Lallemant, Benjamin, Alfonsi, Marc, Aubry, Karine, Mazel, Martine, Becher, François, Perriard, Françoise, Chatelut, Etienne, Thomas, Fabienne

“…Aims Cetuximab associated with cisplatin and 5‐fluorouracil is used to treat patients with inoperable or metastatic head and neck squamous cell carcinomas…”
Get full text

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults by RETAIN, Aurélie, KATTYGNARATH, Darouna, AZARD, Julie, CHATELUT, Etienne, DELBALDO, Catherine, GEOERGER, Birgit, BARROIS, Michel, SERONIE-VIVIEN, Sophie, LECESNE, Axel, VASSAL, Gilles

“…Purpose: The aim of this study was to explore the effect of several demographic, biological, and pharmacogenetic covariates on the disposition of imatinib and…”
Get full text

Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors by Moeung, Sotheara, Chevreau, Christine, Marsili, Sabrina, Massart, Christophe, Fléchon, Aude, Delva, Rémy, Gravis, Gwenaëlle, Lotz, Jean-Pierre, Bay, Jacques-Olivier, Gross-Goupil, Marine, Filleron, Thomas, Delmas, Caroline, Lafont, Thierry, Chatelut, Etienne, Thomas, Fabienne

“…BACKGROUND Etoposide dosing is based on body surface area. We evaluated if further dose individualization would be required for high dose (HD) etoposide within…”
Get full text

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese by SPARREBOOM, Alex, WOLFF, Antonio C, MATHIJSSEN, Ron H. J, CHATELUT, Etienne, ROWINSKY, Eric K, VERWEIJ, Jaap, BAKER, Sharyn D

“…Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in clinical practice…”
Get full text

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study by Moeung, Sotheara, Chevreau, Christine, Broutin, Sophie, Guitton, Jérôme, Lelièvre, Bénédicte, Ciccolini, Joseph, Massart, Christophe, Fléchon, Aude, Delva, Rémy, Gravis, Gwenaëlle, Lotz, Jean-Pierre, Bay, Jacques-Olivier, Gross-Goupil, Marine, Paci, Angelo, Marsili, Sabrina, Malard, Laurence, Chatelut, Etienne, Thomas, Fabienne

“…We aimed to evaluate the performance of therapeutic drug monitoring (TDM) approach in controlling interpatient variability of carboplatin exposure (AUC) in…”
Get full text